Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00250874
Status:
UNKNOWN
Last Update Posted:
2005-11-08
First Post:
2005-11-07
Brief Title:
Myocet Docetaxel Trastuzumab as 1st Line Treatment of Patients With HER-2Neu Positive Metastatic Breast Cancer
Sponsor:
Zeneus Pharma
Organization:
Zeneus Pharma
Organization Data
Organization:
Zeneus Pharma
Class:
INDUSTRY
Study ID:
Myocet 008 L017
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Zeneus Pharma
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None